Macrophage inhibitory factor: Difference between revisions
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
(One intermediate revision by the same user not shown) | |||
Line 1: | Line 1: | ||
<StructureSection load='2ooh' size='350' side='right' caption='Structure of human macrophage inhibitory factor trimer complex with inhibitor, glycerol and sulfate (PDB entry [[2ooh]])' scene='55/551208/Cv/1'> | <StructureSection load='2ooh' size='350' side='right' caption='Structure of human macrophage inhibitory factor trimer complex with inhibitor, glycerol and sulfate (PDB entry [[2ooh]])' scene='55/551208/Cv/1'> | ||
== Function == | == Function == | ||
'''Macrophage inhibitory factor''' '''Macrophage migration inhibitory factor''' (MIF) is an inflammatory cytokine. MIF is released to the blood stream upon stimulation of white blood cells by bacterial antigens<ref>PMID:11032394</ref>. | '''Macrophage inhibitory factor''' or '''Macrophage migration inhibitory factor''' (MIF) is an inflammatory cytokine. '''MIF2''' or '''D-dopachrome tautomerase''' or '''D-dopachrome decarboxylase''' is a pro-inflammatory cytokine which regulates the innate and adaptive immune response<ref>PMID:22507380</ref>. MIF is released to the blood stream upon stimulation of white blood cells by bacterial antigens<ref>PMID:11032394</ref>. | ||
== Relevance == | == Relevance == | ||
Line 14: | Line 14: | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
[[Category:Topic Page]] | [[Category:Topic Page]] |
Latest revision as of 12:21, 21 October 2021
FunctionMacrophage inhibitory factor or Macrophage migration inhibitory factor (MIF) is an inflammatory cytokine. MIF2 or D-dopachrome tautomerase or D-dopachrome decarboxylase is a pro-inflammatory cytokine which regulates the innate and adaptive immune response[1]. MIF is released to the blood stream upon stimulation of white blood cells by bacterial antigens[2]. RelevanceMIF plays a role in various solid and hematologic tumors[3]. MIF is overexpressed in various tumors and is suggested to be the molecular link between chronic inflammation and cancer. MIF has a role in skin inflammation, immune response, disease, tumorigenesis and wound healing[4]. MIF has a role in Alzheimer disease and its inhibition may prevent the disease onset[5]. Structural highlightsMIF contains two different catalytic sites. A phenylpyruvate tautomerase site is located in the N terminal. A . The [6]. Water molecules shown as red spheres. 3D structures of macrophage inhibitory factorMacrophage inhibitory factor 3D structures
|
|
ReferencesReferences
- ↑ Merk M, Mitchell RA, Endres S, Bucala R. D-dopachrome tautomerase (D-DT or MIF-2): doubling the MIF cytokine family. Cytokine. 2012 Jul;59(1):10-7. doi: 10.1016/j.cyto.2012.03.014. Epub 2012 Apr 14. PMID:22507380 doi:http://dx.doi.org/10.1016/j.cyto.2012.03.014
- ↑ Nishihira J. Macrophage migration inhibitory factor (MIF): its essential role in the immune system and cell growth. J Interferon Cytokine Res. 2000 Sep;20(9):751-62. PMID:11032394 doi:http://dx.doi.org/10.1089/10799900050151012
- ↑ Bach JP, Deuster O, Balzer-Geldsetzer M, Meyer B, Dodel R, Bacher M. The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors. Cancer. 2009 May 15;115(10):2031-40. doi: 10.1002/cncr.24245. PMID:19326434 doi:http://dx.doi.org/10.1002/cncr.24245
- ↑ Shimizu T. Role of macrophage migration inhibitory factor (MIF) in the skin. J Dermatol Sci. 2005 Feb;37(2):65-73. PMID:15659324 doi:http://dx.doi.org/10.1016/j.jdermsci.2004.08.007
- ↑ Bacher M, Deuster O, Aljabari B, Egensperger R, Neff F, Jessen F, Popp J, Noelker C, Reese JP, Al-Abed Y, Dodel R. The role of macrophage migration inhibitory factor in Alzheimer's disease. Mol Med. 2010 Mar;16(3-4):116-21. doi: 10.2119/molmed.2009.00123. Epub 2010 Feb, 28. PMID:20200619 doi:http://dx.doi.org/10.2119/molmed.2009.00123
- ↑ Crichlow GV, Cheng KF, Dabideen D, Ochani M, Aljabari B, Pavlov VA, Miller EJ, Lolis E, Al-Abed Y. Alternative chemical modifications reverse the binding orientation of a pharmacophore scaffold in the active site of macrophage migration inhibitory factor. J Biol Chem. 2007 Aug 10;282(32):23089-95. Epub 2007 May 25. PMID:17526494 doi:http://dx.doi.org/10.1074/jbc.M701825200